Healthcare / BiotechnologyNasdaqGS
$2.26
+0.04 (+1.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-62.3M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$130M
P/E
N/A
•EV/EBITDA
6.3x
↓ROE
19.9%
↑Gross Margin
N/A
•Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
42.3%
FCF / Net income
1.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $70.0M · net income $22.4M · FCF $29.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $70.0M | $70.0M | — | — | — | — | $0.00 | $0.00 | $0.00 |
| Net Income | $22.4M | $22.4M | $-69.7M | $-82.4M | $-91.2M | $-125.6M | $-67.3M | $-35.3M | $-8.9M |
| EBITDA | $20.2M | $20.2M | $-78.4M | $-86.0M | $-92.3M | — | — | — | — |
| EPS | — | — | -1.27 | -1.88 | -2.52 | -3.47 | -2.05 | — | — |
| Operating Margin | 28.4% | 28.4% | — | — | — | — | — | — | — |
| Net Margin | 32.0% | 32.0% | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | 0.17 | 0.17 | 0.27 | 0.22 | 0.24 | — | — | — | — |
| Current Ratio | 8.46 | 8.46 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $29.6M | $29.6M | $-62.3M | $-66.8M | $-85.3M | $-102.9M | $-52.3M | $-24.7M | $-8.5M |
| Returns | |||||||||
| ROE | 19.9% | 19.9% | -83.7% | -70.6% | -78.8% | -64.1% | -21.9% | 74.8% | 57.5% |
| Valuation | |||||||||
| EV/EBITDA | 6.28 | 6.28 | — | — | — | — | — | — | — |
| P/B | 1.15 | 1.15 | 1.45 | 1.03 | 0.65 | — | — | — | — |
| Growth & Yield | |||||||||
| EPS Growth | — | — | 32.4% | 25.4% | — | -69.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.27 → n/d
Residual
+2.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.